News

September 6, 2022
IGM Biosciences to Present at Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Sept. 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in three upcoming investor
Additional Formats
June 1, 2022
IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference
MOUNTAIN VIEW, Calif. , June 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in a fireside chat at the 2022
Additional Formats
April 6, 2022
IGM Announces Closing of $230.0 Million Public Offering
MOUNTAIN VIEW, Calif. , April 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing on April 1, 2022 of its previously announced underwritten public offering of 8,695,653 shares of its non-voting common stock and, pursuant to the exercise in full by the
Additional Formats
March 30, 2022
IGM Announces Pricing of $200.0 Million Public Offering
MOUNTAIN VIEW, Calif. , March 30, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its underwritten public offering of 8,695,653 shares of its non-voting common stock at a price to the public of $23.00 per share.
Additional Formats
March 29, 2022
IGM Announces Proposed Public Offering
MOUNTAIN VIEW, Calif. , March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an
Additional Formats
Displaying 1 - 10 of 15